Complement Cascade News Today

Researchers at ETH Zurich have identified a proteomic signature that could recognize long COVID six months after acute infection. Biologically, the signature indicated that the complement system remained active in patients with long COVID six months after infection. Translationally, it could lead to a diagnostic test for long COVID, and suggests that targeting the complement system could be a therapeutic approach to prevent or treat the disorder.

On October 9, 2023, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), sold 12,000 shares of the company.